Zobrazeno 1 - 10
of 206
pro vyhledávání: '"William H. Barry"'
Autor:
William H. Barry, Richard Bell, E Abdi, Maija R.J. Kohonen-Corish, Michelle L. Harrison, Jodi Lynch, Belinda E Kiely, A. Sullivan, Lorraine A. Chantrill, Ray Asghari, Jia Liu, Shorn Goel, Patricia Bastick, Hao Guo, Jane Beith, Bronwyn Murray, Josie Rutovitz
Publikováno v:
JACC: Heart Failure. 7:795-804
The aim of CATS (Cardiotoxicity of Adjuvant Trastuzumab Study) was to prospectively assess clinical, biochemical, and genomic predictors of trastuzumab-related cardiotoxicity (TRC).Cardiac dysfunction is a common adverse effect of trastuzumab. Studie
Autor:
Michele Baltay, Adrienne G. Waks, Jane E. Brock, Sara M. Tolaney, Evisa Gjini, EP Winer, Jennifer Savoie, Daniel G. Stover, Scott J. Rodig, Ian E. Krop, William H. Barry, Deborah A. Dillon
Publikováno v:
Cancer Research. 78:PD6-09
Background: Hormone receptor-positive (HR+) tumors have fewer tumor-infiltrating lymphocytes (TILs) and lower response rates to immune checkpoint inhibitors (ICI), either as single agents or in combination with chemotherapy, than triple negative canc
Autor:
Dimitrios Spentzos, William H. Barry, Cassandra Garbutt, G.M. Cote, Haydn T. Kissick, Mark C. Gebhardt, John Quackenbush, Francis J. Hornicek, Jeff Goldsmith, Katherine A. Janeway, Ahmed Rattani, Katherine E. Hill, Edwin Choy, Antonio R. Perez-Atayde, Marieke L. Kuijjer, Mohamed S. Arredouani, Zhenfeng Duan, Andrew Kelly, Benjamin Haibe-Kains
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-22 (2017)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Background A microRNA (miRNA) collection on the imprinted 14q32 MEG3 region has been associated with outcome in osteosarcoma. We assessed the clinical utility of this miRNA set and their association with methylation status. Methods We integrated codi
Autor:
Luke Walker, Ian E. Krop, Sara M. Tolaney, Rachel A. Freedman, Hao Guo, William H. Barry, EP Winer, Elizabeth V. Lawler, Jerry Younger, Otto Metzger, Nu Lin
Publikováno v:
Cancer Research. 77:P1-12
Background: Brain metastases remain an important cause of death for pts with advanced HER2+ BC. ONT-380 is an oral, potent and selective inhibitor of HER2 capable of penetrating the blood brain barrier in pre-clinical models. We evaluated the safety
Autor:
Georg Pfeiler, Erica L. Mayer, William H. Barry, Otto Metzger, Antonio C. Wolff, P Rastogi, M.J. Piccart, HJ Burstein, Dimitrios Zardavas, Xin-Yun Huang, C Huang-Bartlett, S. Loibl, Maria Koehler, Christian Fesl, Theodora Goulioti, EP Winer, M. Gnant, Katherine E. Miller, AM DeMichele
Publikováno v:
Cancer Research. 78:OT3-05
Background: Cell cycle inhibition is a proven target for novel cancer therapeutics. Palbociclib (P) is an orally active inhibitor of CDK4/6, and arrests the cell cycle at the G1-S transition. P in combination with endocrine therapy (ET) has demonstra
Autor:
Beth Overmoyer, Karleen Habin, William H. Barry, P McMullen, SJ Isakoff, DW Bartenstein, GS Rogers, S Hill, ST Chen
Publikováno v:
Cancer Research. 78:OT2-04
Background Cutaneous metastases occur in approximately 20% of patients (pts) with metastatic breast cancer (mBC) and can be highly symptomatic and distressing. Radiation therapy is frequently used, but progression often occurs quickly. Systemic thera
Autor:
Arti Hurria, Karla V. Ballman, Jacqueline M. Lafky, Linda M. McCall, Debu Tripathy, Hyman B. Muss, William H. Barry, Olwen Hahn, Eric P. Winer, Aminah Jatoi, Maura N. Dickler, Clifford A. Hudis, Harvey J. Cohen, Daneng Li, Bryan P. Schneider
Publikováno v:
Breast cancer research and treatment. 171(2)
BACKGROUND: In hormone receptor-positive advanced breast cancer, a progression-free survival benefit was reported with addition of bevacizumab to first-line letrozole. However, increased toxicity was observed. We hypothesized that functional age meas
Autor:
Shom Goel, Josie Rutovitz, Hao Guo, Ray Asghari, Richard Bell, Jane Beith, Patricia Bastick, Michelle Harrison, Lorraine A. Chantrill, Belinda E Kiely, Jodi Lynch, Bronwyn Murray, Maija R.J. Kohonen-Corish, A. Sullivan, E Abdi, William H. Barry
Publikováno v:
Cancer Research. 75:P4-15
Background: Adjuvant therapy for HER2-positive breast cancer (HBC) often comprises anthracyclines (A) followed by trastuzumab (T). Trastuzumab-related cardiotoxicity (TRC) is T’s primary toxicity, and led 15% of patients in NSABP-B31 to stop T earl
Autor:
Otto Metzger, M. Gnant, C Huang Bartlett, William Fraser Symmans, M.J. Piccart, Katherine E. Miller, Dimitrios Zardavas, Maria Koehler, G. von Minckwitz, EP Winer, P Rastogi, L Chen, P Dubsky, HJ Burstein, Erica L. Mayer, William H. Barry, Christian Fesl, Theodora Goulioti, Antonio C. Wolff, AM DeMichele, S. Loibl
Publikováno v:
Cancer Research. 76:OT1-03
Background: Cell cycle inhibition is a target of interest for novel cancer therapeutics. Palbociclib (P) is an orally active inhibitor of CDK4/6 which arrests the cell cycle at the G1-S transition. P has demonstrated efficacy in phase II and III rand
Autor:
Carolyn N. Krasner, Joyce F. Liu, William H. Barry, Gini F. Fleming, Stephen A. Cannistra, Panagiotis A. Konstantinopoulos, Sarah Farooq, Weixiu Luo, Ursula A. Matulonis, Mary K. Buss, Michael J. Birrer, Susan Schumer, Richard T. Penson, Elizabeth H. Stover, Alexi A. Wright, Susana M. Campos, Don S. Dizon
Publikováno v:
Gynecologic Oncology. 149:24-25